Everything below concerns Cardarine. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-03-09. Where a claim depends on a specific study, the study is described rather than over-claimed.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
| Property | Value | Notes |
|---|---|---|
| Chemical class | PPARδ agonist | Not an anabolic steroid. |
| Common synonyms | GW501516, GW-1516 | Cardarine is an informal name. |
| Appearance | White to off-white powder | Typical for research-grade solid. |
| Solubility class | Poorly soluble in water; soluble in some organic solvents | Such as DMSO or ethanol in laboratory settings. |
| Typical storage temperature | Cool, dry, protected from light | Specific conditions vary by supplier and form. |
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
are the non-conservative and conservative parts of the body force. This result follows from the Helmholtz theorem (also known as the fundamental theorem of vector calculus). The first equation is a pressureless governing equation for the velocity, while the second equation for the pressure is a functional of the velocity and is related to the pressure Poisson equation. The explicit functional form of the projection operator in 3D is found from the Helmholtz theorem:
777 Partners is an American private investment company based in Miami. Founded in 2015, it acquired several soccer clubs, such as Genoa CFC in Italy, Standard Liège in Belgium, Red Star FC in France, CR Vasco da Gama in Brazil, and Hertha BSC in Germany. It also has a minority stake in Spanish club Sevilla FC. The company owned the London Lions basketball team and had a large minority stakeholding in the British Basketball League (BBL). The company is also a shareholder in low-cost carrier Flair Airlines. 777 Partners has been involved in a number of legal and financial proceedings in multiple jurisdictions. In the United States and Belgium, the firm has faced civil lawsuits related to payment disputes, including a Belgian court ruling in 2023 that permitted the seizure of certain assets. In 2024, aircraft linked to the firm were seized in Canada in connection with payment disputes. That same year, its airline Bonza entered voluntary administration, and the operating company of the British Basketball League had its license revoked by British Basketball. In July 2024, A-CAP, an American insurance firm that invested in 777 Partners, informed several football clubs that it had assumed ownership stakes. On October 9, 2024, 777 Partners entered bankruptcy proceedings in the United Kingdom. In August 2026, 777 Partners filed for Chapter 11 bankruptcy in an effort to eliminate the majority of its $2 billion debt.
== Mechanism of action == Immunoliposomes use similar functionality as liposomes with the added measure of conjugating monoclonal antibodies and their fragments to the liposomes. The use of antibodies allow for easy targeting as they can recognize many different types of antigens. Diseased cells typically contain more antigens than healthy cells, which is how antibodies are able to appropriately target certain extracellular domains (depending on antigen overexpression) and kill diseased cells. Liposomal drug delivery combined with antibodies as a targeting ligand are what help immunoliposomes function as an effective drug carrier.
Sources: en.wikipedia.org
=== Premenstrual dysphoric disorder === Fluoxetine is used to treat premenstrual dysphoric disorder, a condition where individuals have affective and somatic symptoms monthly during the luteal phase of menstruation. Taking fluoxetine 20 mg/d can be effective in treating PMDD, though doses of 10 mg/d have also been prescribed effectively.
Dragian Ganymede (ドラグ星人ガニメデ, Doragu Seijin Ganimede): A crab-themed criminal from Planet Drag whom Agent Abrella broke out of prison and equipped with a Hyper Muscle Gear to assist him in attacking the Deka Base, only to be deleted by Deka Blue and Green. Ganymede is voiced by Yūji Kishi (岸 祐二, Kishi Yūji). Jergonian Sukeela (ジャーゴ星人スキーラ, Jāgo Seijin Sukīra): A mantis shrimp–themed criminal from Planet Jergo whom Agent Abrella broke out of prison and equipped with a Hyper Muscle Gear to assist him in attacking the Deka Base, only to be deleted by Deka Yellow and Pink. Sukeela is voiced by Emi Shinohara (篠原 恵美, Shinohara Emi).
In July 2023, TikTok launched a new streaming service called TikTok Music. This service allowed users to listen to, download and share songs. After a dispute with TikTok regarding payouts for artists and regulation of AI-generated music content on the platform, Universal Music Group decided not to renew its licensing agreement, causing its catalogue of 3 million recordings to become unavailable for usage after 2024. This marked the company's first instance of withdrawing its music from a major platform, in contrast to Warner Music, which had recently renewed its own licensing deal with TikTok. In March 2024, Universal Music Publishing Group removed its catalogue of 4 million compositions from TikTok. In April 2024, Taylor Swift's music returned to the platform. TikTok Music was discontinued in November 2024. In December 2025, TikTok launched digital gift cards. In February 2026, TikTok launched Local Feed, a feature intended to help users connect with their community and discover local events and updates. In June 2026, TikTok launched Agentic Hub, a platform that integrates third-party AI applications with its advertising system to support campaign creation, management, and performance evaluation. In July 2026, TikTok introduced new AI literacy measures, including educational guides and enhanced content transparency tools, to help users recognize AI-generated content. In August 2026, TikTok introduced a legacy account setting that allows users to decide what happens to their account after their death.
Sources: en.wikipedia.org
Cardarine is commonly known as GW501516 or GW-1516. These names refer to the same synthetic compound. It is not a brand-name approved medicine.
No, cardarine is not a steroid. It is classified as a PPARδ agonist. Its structure and receptor target differ from anabolic steroids.
No regulatory agency has approved cardarine as a medicine. It was investigated in early research but development was discontinued. It is not available as a prescription drug.
No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.